Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma
作者： Mauricio Burotto , Syed Abbas Ali , Geraldine O’Sullivan Coyne
DOI: 10.1517/14740338.2014.973400
关键词: Tyrosine-kinase inhibitor 、 Internal medicine 、 EGFR inhibitors 、 Gefitinib 、 Clinical trial 、 Erlotinib 、 Afatinib 、 Erlotinib Hydrochloride 、 Medicine 、 Oncology 、 Context (language use) 、 Pharmacology
摘要: Introduction: The past decade has seen the development and widespread use of tyrosine kinase inhibitors (TKIs) targeting a mutated EGFR (mEGFR) for treatment metastatic NSCLC. We discuss main properties TKIs currently recommended mEGFR NSCLC: gefitinib, erlotinib afatinib.Areas covered: mechanism action, pharmacodynamics pharmacokinetics these drugs, with emphasis on historical context their preclinical clinical development, will be covered, including potential resistance mechanisms to first-generation that driven trial design second third generations inhibitors. Six Phase III trials comparing three cisplatin-based chemotherapy upfront NSCLC provide basis comparative safety toxicity analysis between agents. Class-related inhibitors, life-threatening effects, discussed.Expert opinion: Toxicity anal...
elsevier.com
informahealthcare.com参考文章(108)
Victoria M. Rimkunas, Katherine E. Crosby, Daiqiang Li, Yerong Hu, Meghan E. Kelly, Ting-Lei Gu, Jennifer S. Mack, Matthew R. Silver, Xinmin Zhou, Herbert Haack, Analysis of Receptor Tyrosine Kinase ROS1-Positive Tumors in Non–Small Cell Lung Cancer: Identification of a FIG-ROS1 Fusion Clinical Cancer Research. ,vol. 18, pp. 4449- 4457 ,(2012) , 10.1158/1078-0432.CCR-11-3351
Frances A. Shepherd, José Rodrigues Pereira, Tudor Ciuleanu, Eng Huat Tan, Vera Hirsh, Sumitra Thongprasert, Daniel Campos, Savitree Maoleekoonpiroj, Michael Smylie, Renato Martins, Maximiliano van Kooten, Mircea Dediu, Brian Findlay, Dongsheng Tu, Dianne Johnston, Andrea Bezjak, Gary Clark, Pedro Santabárbara, Lesley Seymour, Erlotinib in previously treated non-small-cell lung cancer. The New England Journal of Medicine. ,vol. 353, pp. 123- 132 ,(2005) , 10.1056/NEJMOA050753
Martin L. Sos, Haridas B. Rode, Stefanie Heynck, Martin Peifer, Florian Fischer, Sabine Klüter, Vijaykumar G. Pawar, Cecile Reuter, Johannes M. Heuckmann, Jonathan Weiss, Lars Ruddigkeit, Matthias Rabiller, Mirjam Koker, Jeffrey R. Simard, Matthäus Getlik, Yuki Yuza, Tzu-Hsiu Chen, Heidi Greulich, Roman K. Thomas, Daniel Rauh, Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation Cancer Research. ,vol. 70, pp. 868- 874 ,(2010) , 10.1158/0008-5472.CAN-09-3106
Clara Lemos, Elisa Giovannetti, Paolo A Zucali, Yehuda G Assaraf, George L Scheffer, Tahar van der Straaten, Armida D’Incecco, Alfredo Falcone, Henk-Jan Guchelaar, Romano Danesi, Armando Santoro, Giuseppe Giaccone, Carmelo Tibaldi, Godefridus J Peters, Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. Pharmacogenomics. ,vol. 12, pp. 159- 170 ,(2011) , 10.2217/PGS.10.172
Ken Takezawa, Valentina Pirazzoli, Maria E. Arcila, Caroline A. Nebhan, Xiaoling Song, Elisa de Stanchina, Kadoaki Ohashi, Yelena Y. Janjigian, Paula J. Spitzler, Mary Ann Melnick, Greg J. Riely, Mark G. Kris, Vincent A. Miller, Marc Ladanyi, Katerina Politi, William Pao, HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discovery. ,vol. 2, pp. 922- 933 ,(2012) , 10.1158/2159-8290.CD-12-0108
Annette O. Walter, Robert Tjin Tham Sjin, Henry J. Haringsma, Kadoaki Ohashi, Jing Sun, Kwangho Lee, Aleksandr Dubrovskiy, Matthew Labenski, Zhendong Zhu, Zhigang Wang, Michael Sheets, Thia St Martin, Russell Karp, Dan van Kalken, Prasoon Chaturvedi, Deqiang Niu, Mariana Nacht, Russell C. Petter, William Westlin, Kevin Lin, Sarah Jaw-Tsai, Mitch Raponi, Terry Van Dyke, Jeff Etter, Zoe Weaver, William Pao, Juswinder Singh, Andrew D. Simmons, Thomas C. Harding, Andrew Allen, Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC Cancer Discovery. ,vol. 3, pp. 1404- 1415 ,(2013) , 10.1158/2159-8290.CD-13-0314
Vincent A Miller, Vera Hirsh, Jacques Cadranel, Yuh-Min Chen, Keunchil Park, Sang-We Kim, Caicun Zhou, Wu-Chou Su, Mengzhao Wang, Yan Sun, Dae Seog Heo, Lucio Crino, Eng-Huat Tan, Tsu-Yi Chao, Mehdi Shahidi, Xiuyu Julie Cong, Robert M Lorence, James Chih-Hsin Yang, Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial Lancet Oncology. ,vol. 13, pp. 528- 538 ,(2012) , 10.1016/S1470-2045(12)70087-6
F A L M Eskens, C H Mom, A S T Planting, J A Gietema, A Amelsberg, H Huisman, L van Doorn, H Burger, P Stopfer, J Verweij, E G E de Vries, A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours British Journal of Cancer. ,vol. 98, pp. 80- 85 ,(2008) , 10.1038/SJ.BJC.6604108
Ayodele Ayoola, Amit Barochia, Kiran Belani, Chandra P. Belani, Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update. Cancer Investigation. ,vol. 30, pp. 433- 446 ,(2012) , 10.3109/07357907.2012.666691
C.-H. Yun, K. E. Mengwasser, A. V. Toms, M. S. Woo, H. Greulich, K.-K. Wong, M. Meyerson, M. J. Eck, The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP Proceedings of the National Academy of Sciences of the United States of America. ,vol. 105, pp. 2070- 2075 ,(2008) , 10.1073/PNAS.0709662105